Use and Safety of Immunotherapeutic Management of N-Methyl-D-Aspartate Receptor Antibody Encephalitis A Meta-analysis
JAMA NEUROLOGY, cilt.78, sa.11, ss.1333-1344, 2021 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 78 Sayı: 11
- Basım Tarihi: 2021
- Doi Numarası: 10.1001/jamaneurol.2021.3188
- Dergi Adı: JAMA NEUROLOGY
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, CAB Abstracts, EMBASE, MEDLINE, Psycinfo
- Sayfa Sayıları: ss.1333-1344
- Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
- Hacettepe Üniversitesi Adresli: Hayır
Özet
IMPORTANCE Overall, immunotherapy has been shown to improve outcomes and reduce relapses in individuals with N-methyl-D-aspartate receptor (NMDAR) antibody encephalitis (NMDARE); however, the superiority of specific treatments and combinations remains unclear.